# Post-Trade Review

> Review Date: 2026-02-06
> Trade ID: 2026-01-15-AAPL-LONG
> Reviewer: Owen

---

## 1. Trade Summary

- **Trade ID**: 2026-01-15-AAPL-LONG
- **Symbol**: AAPL
- **Direction**: Long
- **Investment Bucket**: Long-term Compounder
- **Strategy Used**: equity/compounder-accumulation
- **Hold Period**: 21 days (15 from first tranche, 14 from second)
- **Entry Price**: $221.28 (avg)
- **Exit Price**: $241.80
- **Realized P&L**: $7,182 (+9.3%)
- **Position Size**: 7.2% of portfolio
- **OPRMS at Entry**: DNA S, Timing B
- **OPRMS at Exit**: DNA S, Timing B (unchanged)

---

## 2. Thesis Accuracy

**Original Thesis:**
> Apple Intelligence will drive a Services revenue inflection, pushing Services growth from 14% to 20%+ YoY within the next 3 quarters, as AI features create new monetization channels and accelerate the iPhone upgrade cycle.

- **Verdict**: Partially Validated -- the stock moved in the right direction, but the core thesis (Services inflection from Apple Intelligence) was never tested because the position was closed before the Q1 2026 earnings report that would have provided the first real data point.
- **Variant view accuracy**: Unclear. Market may have been re-rating AAPL for AI narrative regardless of Services data. The position profited from narrative momentum, not fundamental confirmation.
- **Timeline accuracy**: Too early to assess. The thesis had a 3-quarter horizon; position was held for 3 weeks.

| Dimension | Score (1-10) | Notes |
|-----------|-------------|-------|
| Thesis correctness | 6 | Directionally right but untested on merits |
| Timing accuracy | 5 | Not enough time to evaluate |
| Sizing appropriateness | 7 | 7.2% was reasonable for Timing B, left room to add |
| Execution quality | 8 | Good entry below action price, clean exit |
| **Overall process score** | **5** | Low because the exit violated compounder discipline |

---

## 3. Three Analytical Tensions

### Tension 1: Should a compounder position be trimmed before earnings?

**Case For**: AAPL was up 9.3% in 3 weeks. Earnings are binary events. Taking profit protects against a potential 10-15% drawdown on a miss. Risk management is always valid.

**Case Against**: The entire compounder strategy is built on holding through volatility. Pre-earnings exits convert long-term positions into swing trades. The edge of compounding IS enduring short-term pain for long-term gain. If the thesis is intact, holding through earnings is the correct action.

**What Tipped the Scales**: The 9.3% unrealized gain created loss aversion -- the fear of giving back profits outweighed the discipline of the strategy.

**In Hindsight**: This was an emotional exit disguised as risk management. If the compounder strategy says "no price-based exits," then pre-earnings profit-taking is a violation. Need a pre-defined earnings protocol for compounders: either always hold, or define specific conditions for reduction (e.g., position >20% of portfolio).

### Tension 2: Was the position size appropriate for the conviction level?

**Case For**: 7.2% for a DNA S / Timing B stock is well within the 12.5% maximum (25% x 0.5). The plan was to scale in over 3 tranches, and only 2 of 3 triggered. Conservative sizing for a new position is prudent.

**Case Against**: If this is truly a DNA S conviction stock and the thesis was strong enough to write a full investment memo, why was the initial allocation only 7.2%? The missed third tranche at $205 means the position was undersized for the conviction level. At Timing B, the max was 12.5% -- we got to only 58% of max.

**What Tipped the Scales**: The discipline of the scaling plan worked correctly -- the third tranche level was not reached, so it wasn't bought. This is good process.

**In Hindsight**: The scaling plan was well-designed. The issue is not sizing but hold period. A properly sized compounder should be held for years, not weeks.

### Tension 3: Should the trade have been classified as a compounder or a catalyst trade?

**Case For compounder**: AAPL is a DNA S stock with a 20+ year compounding thesis. The Services revenue inflection is a long-term structural story, not a one-time event.

**Case Against**: The actual behavior (3-week hold, pre-earnings exit, profit-taking on momentum) looks like a catalyst trade (catalyst = pre-earnings AI narrative run-up). The thesis even referenced "3 quarters" -- a specific timeline more suited to catalyst-driven strategy.

**What Tipped the Scales**: It was classified as a compounder at entry but managed as a catalyst trade during the holding period.

**In Hindsight**: This should have been entered as a catalyst-driven trade with explicit pre-earnings profit targets, OR committed fully as a compounder with no pre-earnings exit. The hybrid approach violated both strategies' rules.

---

## 4. Observable Milestones

| Milestone | Expected Timeline | Actual Outcome | Status |
|-----------|------------------|----------------|--------|
| Services revenue growth > 20% YoY | Q1 2026 earnings (Jan 30) | Position closed before earnings | Never Tested |
| Apple Intelligence subscription launch | H1 2026 | Not yet launched at time of exit | Pending |
| iPhone upgrade cycle acceleration | Q4 2025 - Q2 2026 | Early data mixed, no clear signal | Pending |

### Kill Conditions Review
| Kill Condition | Triggered? | Notes |
|----------------|-----------|-------|
| Services growth < 12% for 2Q | No | Never tested -- exited before earnings |
| iPhone units -10% for 2Q | No | No relevant data during hold period |
| Gross margin < 44% for 2Q | No | No relevant data during hold period |

**Were kill conditions well-designed?** Yes, the kill conditions were fundamental and measurable. However, they were all earnings-dependent, meaning they could only be evaluated quarterly. For a 3-week hold, they were never relevant. This reinforces that the trade was misclassified as a compounder.

---

## 5. Execution Quality

### Entry
- **Planned vs. actual entry**: $225 vs. $221.28 (avg)
- **Slippage**: -166 bps (favorable -- filled below action price)
- **Entry timing**: Good. First tranche caught a dip, second tranche caught a pullback.
- **Tranche execution notes**: 2 of 3 tranches executed. Third ($205) never triggered. Clean limit order fills on both entries.

### Exit
- **Planned exit trigger**: Kill conditions (thesis invalidation only, per compounder strategy)
- **Actual exit trigger**: Pre-earnings risk reduction / profit-taking
- **Exit timing**: Arguably good for a swing trade, bad for a compounder
- **Emotional influence**: Significant. Loss aversion (protecting the +9.3% gain) drove the exit more than any analytical signal.

### Sizing
- **Planned vs. actual position**: 10% vs. 7.2%
- **Sizing appropriate for conviction?** Slightly undersized but the gap was due to the third tranche not triggering, which is good discipline.
- **Hindsight sizing adjustment**: Sizing was fine. The problem was not holding, not sizing.

---

## 6. Lessons Extracted

### Strategy-Level
- The compounder accumulation strategy needs an explicit **earnings-bridge protocol**: should the position be reduced pre-earnings, and if so, under what conditions? Currently the strategy says "no price-based exits" but is silent on earnings risk management for new positions (held < 1 quarter).
- Need to distinguish between **mature compounders** (held > 1 year, thesis validated through multiple earnings) and **new compounders** (recently initiated, thesis untested). Different rules may apply.

### Risk-Level
- A position that has gained > 8% in < 30 days should trigger a **discipline check**: is this still a long-term position or has it become a swing trade? Make the classification change explicit rather than implicit.

### Knowledge-Level
- AAPL DNA rating of S remains appropriate. The stock quality is not in question.
- Timing rating should potentially be upgraded from B to A given the breakout behavior during the hold period.

### Personal
- Loss aversion is a persistent behavioral pattern. Pre-defining exit rules eliminates the decision from the emotional moment.
- Need to accept that compounder positions WILL have drawdowns after good runs. This is expected, not a reason to exit.

---

## 7. Feedback Actions

| Action | Target | Priority | Status |
|--------|--------|----------|--------|
| Add earnings-bridge protocol to compounder strategy | Strategy Library: `strategies/equity/compounder-accumulation.md` | High | Pending |
| Add "new vs. mature compounder" distinction to strategy doc | Strategy Library: `strategies/equity/compounder-accumulation.md` | Medium | Pending |
| Add discipline check rule: > 8% gain in < 30 days triggers classification review | Risk Desk | Medium | Pending |
| Review AAPL Timing rating: B -> A? | Knowledge Base OPRMS | Low | Pending |

---

## Bias Check

- [x] Hindsight bias: judging with information I didn't have? -- Attempted to evaluate based on information available at exit time
- [x] Outcome bias: letting P&L color process assessment? -- Yes, the +9.3% gain makes this feel like a good trade, but the process score is 5/10
- [x] Confirmation bias: selectively remembering evidence? -- Checked: not selectively filtering
- [x] Recency bias: overweighting recent events? -- The pre-earnings anxiety may have been amplified by recent market volatility
- [x] Self-serving bias: credit for wins, blame for losses? -- Acknowledged that the profit was partly luck (market momentum) not skill (thesis confirmation)
